Status:

UNKNOWN

Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment

Lead Sponsor:

Accexible

Conditions:

Mild Cognitive Impairment

Dementia

Eligibility:

All Genders

55-90 years

Phase:

NA

Brief Summary

Validate speech analysis AI models: * To contrast the accuracy of acceXible's platform as a screening tool in the detection of people with cognitive impairment and mild dementia. * To evaluate the co...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Adult patients 55+ years of age with suspected MCI or diagnosis of dementia and obtains a score greater than 20 on the MMSE.
  • Patients must have agreed to participate in the study and have voluntarily signed the informed consent.
  • (Healthy) Participants without a diagnosis neurological, or psychiatric disorders. Or taking medication that can affect cognitive abilities.
  • Exclusion Criteria
  • To have received a diagnosis of a significant psychiatric disorder or other cognitive impairment not due to neurodegeneration.
  • To have significant vision problems that would affect the ability to perceive visual stimuli.
  • To have significant hearing problems that would affect the ability to understand verbal cues.

Exclusion

    Key Trial Info

    Start Date :

    January 1 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 31 2022

    Estimated Enrollment :

    300 Patients enrolled

    Trial Details

    Trial ID

    NCT05340218

    Start Date

    January 1 2019

    End Date

    December 31 2022

    Last Update

    April 22 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Centro de Prevención de Deterioro Cognitivo

    Madrid, Spain, 28006

    Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment | DecenTrialz